Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, ...
Jan 21, 2021
0
2